SC
RDHL

Sculptor Capital’s Redhill Biopharma RDHL Stock Holding History

Sculptor Capital’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-135
Closed -$1.09M – 771
2020
Q4 		$1.09M Hold
135
– – ﹤0.01% 342
2020
Q3 		$1.38M Buy
135
+109
+419% +$894K 0.01% 254
2020
Q2 		$176K Buy
+26
New +$179K ﹤0.01% 243

Other funds holding RDHL

II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Sculptor Capital's RDHL Position: Q1 2021 in Review

Sculptor Capital sold out of Redhill Biopharma (RDHL) in Q1 2021, closing a stake of 135 shares — an estimated $1.09M sold.

Sculptor Capital first reported a position in RDHL in Q2 2020 and held it in 3 quarters. The position peaked at $1.38M in Q3 2020. 55 funds tracked by Wall St. Rank hold RDHL as of Q1 2021.

  • Sculptor Capital reported no remaining Redhill Biopharma position as of Q1 2021 after selling out during the quarter.
  • Sculptor Capital sold 135 Redhill Biopharma shares in Q1 2021, an estimated $1.09M.
  • Sculptor Capital first reported a position in Redhill Biopharma in Q2 2020 and held it in 3 quarters.
  • Sculptor Capital's Redhill Biopharma position peaked at $1.38M in Q3 2020.
  • 55 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2021.

Based on Sculptor Capital's 13F filing for Q1 2021, filed 14 May 2021.